

WILMER CUTLER PICKERING HALE AND DORR LLP

2004 LIFE SCIENCES

Life sciences leaders turn to Wilmer Cutler Pickering Hale
and Dorr for legal advice and business advantage. We provide
incisive solutions to the business challenges facing biotechnology,
pharmaceutical, heal thcare and medical device companies at all
stages of growth. For over four decades, we have represented life
sciences clients in venture financings, public offerings, mergers
and acquisitions, licensing agreements and landmark collaborations,
and have defended their innovations in critical patent litigation.

Mergers and Acquisitions



has agreed to acquire Kendro Laboratory Products from SPX Corporation

\$835,000,000 Pending*



has acauired ViPS \$160,000,000

August 2004



has been acauired by Aeterna Laboratories \$50,000,000 March 2004



has been acquired by Medtronic \$45,000,000

(plus potential earnout)

November 2004



has been acquired by

Strategic Alliances and Collaborations



License of liposome technology from Zilip-Pharma for use in Kogenate® hemophilia product

//// MILLENNIUM

License to GlaxoSmithKline of European marketing rights to Integrilin® heart disease drug



Sale to Genzyme $of\ commercialization\ rights\ to$ Synvisc® pain relief product



Collaboration with Gilead Sciences for treatments of hepatitis C virus infection



Marketing information engagements by major pharmaceutical companies



Small molecule alliances with Johnson & Johnson and Novartis



Merck to identify targets for the development of small molecule oncology agents



US license and supply agreement with Reliant Pharmaceuticals for Omacor® product



Strategic partnership with Wyeth to develop therapeutics for neurological disorders



Lung cancer drug discovery collaboration with Abbott Laboratories



Agreement with Dow AgroSciences for collaborative research



Advice on licensing and distribution matters



Research collaboration with Lexicon Genetics



Collaboration with McNeil for lcagen's sickle cell disease product

Public Offerings and Rule 144A Placements



Pentax

\$48,000,000 December 2004

eye tech

Counsel to Issuer

December 2004

0% Convertible Senior Subordinated Notes due 2024

\$500,000,000 Counsel to Issuer September 2004



Initial Public Offering of Common Stock \$156,975,000 Counsel to Issuer February 2004



\$81,200,000 Counsel to Issuer July 2004



Initial Public Offering of Common Stock



February 2004



Initial Public Offering of Common Stock \$78,300,000 Counsel to Underwriters



Initial Public Offering of Common Stock \$75,000,000 Counsel to Underwriters May 2004



May 2004



\$42,770,000 Counsel to Issuer June 2004

PHARMetrics

\$8,000,000

Fourth Round

November 2004







Venture Capital and PIPEs Financings



\$40,000,000 Fourth Round May 2004



\$35,000,000 PIPEs Financing December 2004



\$20,500,000 February 2004



\$29,000,000 Second Round October 2004



December 2004

\$10,000,000 First Round



£20,000,000 First Round May 2004



\$20,000,000 Late Stage August 2004



Series A Extension

December 2004

COUNSEL OF CHOICE TO LIFE SCIENCES LEADERS...FROM BIOTECH TO MEDICAL DEVICES.

For further information, please visit our website at wilmerhale.com

Baltimore

Beijing

Berlin

Boston

Brussels

London

Munich

New York

Northern Virginia

Oxford

Waltham

Washington

Wilmer Cutler Pickering
Hale and Dorr LLP is a Delaware
limited liability partnership.
Our UK offices are operated
under a separate Delaware
limited liability partnership.